Clinical trials: Hypertension, Uncontrolled
Hypertension, Cardiovascular Diseases
Global Paradise System US Post Approval Study
The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood…
- Conditions
- Hypertension, Cardiovascular Diseases, Vascular Diseases
- Trial name
- US GPS (NCT06297291)
- Testing
- Paradise Ultrasound Renal Denervation Treatment
- Where
- 46 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- ReCor Medical, Inc.
Hypertension
Blood Pressure Control of Nifedipine GITS 60mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapyo-therapy.
To evaluate antihypertensive efficacy and tolerability of Nifedipine GITS 60mg treated for 8 weeks in Chinese hypertensive subjects who failed to achieve BP control with the starting-dose antihypertensive monotherapy.
- Trial name
- ADEPT (NCT02413515)
- Testing
- Nifedipine (Adalat GITS, BAY1040)
- Where
- 14 sites in China
- Volunteers
- 278 people
- Sponsor
- Bayer
Hypertension
Efficacy/Safety of Amlodipine Plus Losartan Versus Losartan in Patients With Essential Hypertension
The purpose of this study is to evaluate of efficacy and safety of amlodipine plus losartan and losartan alone in patients with essential hypertension inadequately controlled on losartan monotherapy.
- Trial name
- NCT00940680
- Testing
- Amlodipine plus Losartan, Losartan
- Where
- South Korea
- Volunteers
- 142 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.
The purpose of this study is to evaluate the blood pressure lowering effects of an amlodipine/losartan combination treatment and losartan/Hydrochlorothiazide combination treatment in patients with essential hypertension…
- Trial name
- NCT01828359
- Testing
- Amosartan® tab, Cozaar® plus pro tab
- Volunteers
- 199 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
Telmisartan Tab Hypertension
To assess the efficacy of telmisartan in hypertensive patients with high cardiovascular risk
- Trial name
- NCT00890084
- Testing
- Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)
- Volunteers
- 2,913 people
- Sponsor
- Boehringer Ingelheim
Uncontrolled Hypertension
Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2)
An international, multi-center, prospective, randomized, controlled study of the safety and effectiveness of renal denervation in patients with uncontrolled hypertension.
- Trial name
- HTN-2 (NCT00888433)
- Testing
- Renal Denervation (Symplicity® Renal Denervation System)
- Where
- 20 sites in Australia, Austria and 8 more
- Volunteers
- 106 people
- Sponsor
- Medtronic Vascular
Hypertension
Sham Controlled Study of Renal Denervation for Subjects With Uncontrolled Hypertension
To demonstrate that non-invasive renal denervation is safe and shows a net difference in blood pressure reduction when compared to sham in subjects with uncontrolled hypertension.
- Trial name
- WAVE_IV (NCT02029885)
- Testing
- Investigational Therapy (Surround Sound)
- Where
- 28 sites in Australia, Austria and 6 more
- Volunteers
- 132 people
- Sponsor
- Kona Medical Inc.
Open Angle Glaucoma, Ocular Hypertension
Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure
The purpose of this study is to demonstrate superior intraocular pressure (IOP) control with travoprost 0.004% / timolol 0.5% compared to beta-blocker monotherapy in participants with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT02003391
- Testing
- Beta-blocker monotherapy, Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution
- Volunteers
- 157 people
- Sponsor
- Alcon Research
Hypertension, Renal Insufficiency, Chronic
A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.
The purpose of this research study is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to the background antihypertensive therapy in patients with uncontrolled blood pressure and chronic kidney…
- Trial name
- INSPIRE-CKD (NCT04162366)
- Testing
- Aprocitentan 25 mg
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Uncontrolled Hypertension
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension
This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of different doses of SAL0140 in uncontrolled hypertension.
- Trial name
- NCT07654140
- Testing
- SAL0140
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Hypertension
Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter
The Study objective is to assess the performance of the Vessix V2 Renal Denervation System for the treatment of uncontrolled hypertension using an innovative percutaneous Radio Frequency (RF) balloon catheter renal denervation…
- Trial name
- REDUCE-HTN (NCT01541865)
- Testing
- Renal Denervation
- Where
- 26 sites in Australia, Austria and 6 more
- Volunteers
- 146 people
- Sponsor
- Boston Scientific Corporation
Resistant Hypertension
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
The purpose of this 20-week randomized double-blind study in patients with resistant hypertension (rHTN) is to evaluate the efficacy, safety, and tolerability, of different doses of XXB750 administered as subcutaneous (SC)…
- Trial name
- NCT05562934
- Testing
- XXB750 drug
- Where
- 78 sites in United States, Australia and 14 more
- Volunteers
- 189 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.
The purpose of this study was to evaluate the efficacy and the safety of a fixed-dose combination in capsule of Amlodipine 5mg/ Bisoprolol fumarate 5mg/ Perindopril arginine 5mg, and free monotherapy at the same dose in patients…
- Trial name
- NCT05288400
- Testing
- Amlodipine 5mg + bisoprolol fumarate 5mg + perindopril arginine 5mg, Norvasc 5mg tablet, Concor 5mg tablet
- Where
- 15 sites in Russia
- Volunteers
- 150 people
- Sponsor
- Servier
Resistant Hypertension, Uncontrolled Hypertension
Rapid Renal Sympathetic Denervation for Resistant Hypertension II
This is a global, multi-center, prospective, randomized, controlled study of the safety and effectiveness of renal denervation with the OneShot Renal Denervation System in patients with uncontrolled hypertension.
- Conditions
- Resistant Hypertension, Uncontrolled Hypertension, Renal Artery Ablation
- Trial name
- RAPID II (NCT01939392)
- Testing
- Renal Denervation (OneShot™ Renal Denervation System)
- Where
- Italy
- Sponsor
- Medtronic Endovascular
Hypertension (HTN)
QLS1410 in Participants With Uncontrolled Hypertension
The goal of this clinical trial is to measure the efficacy and safety of QLS1410 in participants with uncontrolled hypertension (uHTN) or treatment-resistant hypertension (rHTN).
- Trial name
- NCT07489612
- Testing
- Dose 1 of QLS1410, Dose 2 of QLS1410, Dose 3 of QLS1410
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Hypertension
Device Based Therapy in Hypertension Extension Trial
This clinical investigation is designed to describe the long-term safety and efficacy of the CVRx Rheos Baroreflex Hypertension Therapy System in patients who participated in the DEBuT-HT study beyond the original follow up…
- Trial name
- DEBuT-HET (NCT00710294)
- Testing
- CVRx Rheos Baroreflex Hypertension Therapy System
- Where
- 5 sites in Germany, Netherlands and 1 more
- Volunteers
- 50 people
- Sponsor
- CVRx, Inc.
Essential Hypertension
Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan
The main objective of the study will be to assess the efficacy and safety of Sacubitril/Allisartan (240mg) and Amlodipine (5mg) in patients with essential hypertension uncontrolled after 4-week treatment with…
- Trial name
- NCT07704697
- Testing
- Experimental: Sacubitril/Allisartan and Amlodipine Group, Active Comparator: Sacubitril/Allisartan Group
- Where
- China
- Volunteers
- 346 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Glaucoma, Ocular Hypertension
Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy
The purpose of this study was to evaluate the safety and efficacy of adding AZARGA® as a single agent to prostaglandin monotherapy in patients with either ocular hypertension or primary open-angle glaucoma.
- Trial name
- NCT01263444
- Testing
- Brinzolamide 1% / timolol 0.5% Fixed Combination, Habitual prostaglandin monotherapy
- Volunteers
- 47 people
- Sponsor
- Alcon Research
Hypertension Resistant to Conventional Therapy
A Study to Evaluate Safety and Efficacy of the Redy™ Renal Denervation System in the Treatment of Patients With Uncontrolled Hypertension
The ReDy™ System (Renal Dynamics) is a renal denervation device incorporating a variety of ablation features and technical improvements over previously designed systems into a single product.
- Trial name
- NCT02690909
- Testing
- Redy™ Renal Denervation System
- Where
- 10 sites in Belgium, Germany and 6 more
- Volunteers
- 55 people
- Sponsor
- Renal Dynamics GmbH
Hypertension
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypertension
- Trial name
- NCT05968430
- Testing
- lorundrostat
- Where
- 177 sites in United States, Australia and 11 more
- Volunteers
- 1,076 people
- Sponsor
- Mineralys Therapeutics Inc.